New AfPA Video Urges Distinct Names, Comprehensive Testing for Biosimilars
The Alliance for Patient Access released today a new policy video offering a vital prescription for safe use of biosimilars: distinct naming conventions and comprehensive testing.
2014 in Review: The 7 Trends That Shaped Patient Access
Patient access encountered a range of challenges in 2014 – some old, some new. Here’s a look back at the top seven issues that drove physicians to advocate for their patients this year.
Access, Prevention Key to Reducing Preterm Birth
Lowering infant mortality rates begins with reducing preterm births, a recent briefing on Capitol Hill conveyed.
Do Profits – or Patients – Benefit from 340B Growth?
Under the Affordable Care Act, fewer Americans are now uninsured. So why does the government’s discount drug problem for hospitals treating uninsured patients continue to expand?
Comprehensive Medication Management: Collaborating for Better Care, Lower Costs
Getting patients’ medications right could save $290 million in avoidable medical spending, Terry McInnis, MD explained in a recent Patient Advocacy Leaders Summit webinar.
Perinatal Providers Stand by FDA Indication in New RSV Prevention Guidelines
The National Perinatal Association’s 2015 guidelines for preventative RSV (respiratory syncytial virus) treatment send a clear message about protecting pre-term infants: the FDA indication stands.
New IfPA Policy Brief Examines Abuse-deterrent Pain Medications
Abuse-deterrent formulations mark a valuable step toward curbing prescription pain pill abuse, suggests a new Institute for Patient Access policy brief.
Panel Explores Value, Challenges of Clinical Trial Participation
Participating in a clinical trial offers patients unprecedented access to investigative treatments – and an unparalleled opportunity to give back to society.
Do Clinical Pathways Inhibit Cancer Care?
Clinical pathways could be the route to less transparent, more restricted cancer care.
New Campaign Touts Novel Cancer Therapies
A new campaign is raising public awareness about a different way to fight cancer –immuno-oncology, or I-O therapies.
